CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended	6 Months Ended
Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Operating expenses
Research and development expenses	$ 36,317	$ 21,821	$ 63,772	$ 43,350
Selling, general and administrative expenses	5,400	6,633	11,877	12,787
Loss from operations	(41,717)	(28,454)	(75,649)	(56,137)
Gain/(loss) from the change in fair value of derivative liabilities	2,066	(6,784)	8,408	(8,979)
Financial investment income	1,996	2,982	4,332	6,237
Related party loan interest income	1,222	1,001	2,445	1,991
Interest expense	(613)	0	(1,025)	0
Other gain, net	1,053	148	823	182
Loss before income taxes	(35,993)	(31,107)	(60,666)	(56,705)
Income tax expense	395	303	1,018	477
Net loss	$ (36,388)	$ (31,410)	$ (61,684)	$ (57,182)
Weighted-average number of shares outstanding – basic (in shares)	276,355	275,632	276,309	275,563
Weighted-average number of shares outstanding – diluted (in shares)	276,355	275,632	276,309	275,563
Net loss per share basic (in dollars per share)	$ (0.13)	$ (0.11)	$ (0.22)	$ (0.21)
Net loss per share diluted (in dollars per share)	$ (0.13)	$ (0.11)	$ (0.22)	$ (0.21)

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Name:	us-gaap_EarningsPerShareBasic
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.